for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Nantkwest Inc

NK.O

Latest Trade

9.58USD

Change

-0.09(-0.93%)

Volume

1,783,473

Today's Range

8.74

 - 

9.83

52 Week Range

1.35

 - 

15.70

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.67
Open
9.36
Volume
1,783,473
3M AVG Volume
21.01
Today's High
9.83
Today's Low
8.74
52 Week High
15.70
52 Week Low
1.35
Shares Out (MIL)
108.59
Market Cap (MIL)
1,050.09
Forward P/E
-12.72
Dividend (Yield %)
--

Next Event

NantKwest Inc Annual Shareholders Meeting

Latest Developments

More

NantKwest Names Richard Adcock Chief Executive Officer

Nantkwest And Immunitybio Sign Collaboration Agreement For Joint Development And Commercialization Of Covid-19 Vaccine

NantKwest Announces Pricing Of Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Nantkwest Inc

NantKwest, Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.

Industry

Biotechnology & Drugs

Contact Info

3530 John Hopkins Ct

SAN DIEGO, CA

92121-1121

United States

+1.858.6330300

https://www.nantkwest.com/

Executive Leadership

Patrick Soon-Shiong

Executive Chairman of the Board

Barry J. Simon

President, Chief Administrative Officer, Director

Richard Adcock

Chief Executive Officer

Sonja Nelson

Chief Financial Officer

Frederick W. Driscoll

Lead Independent Director

Key Stats

2.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-1.200

2018

-1.220

2019

-0.700

2020(E)

-0.775
Price To Earnings (TTM)
--
Price To Sales (TTM)
10,606.97
Price To Book (MRQ)
7.07
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.52
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-49.35
Return on Equity (TTM)
-44.55

Latest News

Latest News

BRIEF-NantKwest Announces Pricing Of Public Offering Of Common Stock

* NANTKWEST ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Nantkwest Announces Proposed Public Offering Of Common Stock

* NANTKWEST ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-ImmunityBio, NantKwest Sign COVID-19 Joint Development, Manufacturing, Marketing Agreement

* IMMUNITYBIO & NANTKWEST SIGN COVID-19 JOINT DEVELOPMENT, MANUFACTURING AND MARKETING AGREEMENT; IMMUNITYBIO SELECTED FOR ‘OPERATION WARP SPEED’ TO DEVELOP NOVEL ADENOVIRUS COVID-19 VACCINE

BRIEF-Be The Match Biotherapies, Nantkwest Collaborate To Develop Covid-19 treatment

* BE THE MATCH BIOTHERAPIES AND NANTKWEST ANNOUNCE COLLABORATION TO ACCELERATE DEVELOPMENT OF CELL THERAPY TO PREVENT COVID-19 DEATHS

BRIEF-Nantkwest Reports FDA Authorization Of IND Application For Mesenchymal Stem Cell Product For The Treatment Of Severe Covid-19 Patients

* NANTKWEST ANNOUNCES FDA AUTHORIZATION OF IND APPLICATION FOR MESENCHYMAL STEM CELL PRODUCT FOR THE TREATMENT OF SEVERE COVID-19 PATIENTS

BRIEF-NantKwest And ImmunityBio To Initiate Phase 2 Study Of Immunotherapy For Metastatic Pancreatic Cancer

* NANTKWEST AND IMMUNITYBIO TO INITIATE A PHASE 2 STUDY OF IMMUNOTHERAPY FOR METASTATIC PANCREATIC CANCER

BRIEF-Nantkwest And Immunitybio Announce Therapeutics And Vaccines For Combatting Covid-19

* NANTKWEST AND IMMUNITYBIO ANNOUNCE THERAPEUTICS AND VACCINES FOR COMBATTING COVID-19; CLINICAL TRIALS ANTICIPATED TO BEGIN THIS QUARTER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up